Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4 is a research paper published in Neoplasia (2020). On theSindex it has a DataRank of 0. It has been cited 29 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: CA046592
National Cancer Institute
Grant: CA178610
National Cancer Institute
Grant: P30 CA069533
National Cancer Institute
Grant: P50 CA097186
National Cancer Institute
Grant: P50 CA186786
Canadian Institutes of Health Research
Grant: PJT-156150
Gilead Sciences
Grant: GSE132062
NCI NIH HHS
Grant: P30 CA046592
NCI NIH HHS
Grant: R01 CA178610
National Institutes of Health
U.S. Department of Defense
FWCI
2.30
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells
Additional file 1 of An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells